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https://doi.org/10.1016/j.celrep.2021.109252SUMMARYHeme is an iron-containing porphyrin of vital importance for cell energetic metabolism. High rates of heme
synthesis are commonly observed in proliferating cells. Moreover, the cell-surface heme exporter feline leu-
kemia virus subgroup C receptor 1a (FLVCR1a) is overexpressed in several tumor types. However, the rea-
sons why heme synthesis and export are enhanced in highly proliferating cells remain unknown. Here, we
illustrate a functional axis between heme synthesis and heme export: heme efflux through the plasma mem-
brane sustains heme synthesis, and implementation of the two processes down-modulates the tricarboxylic
acid (TCA) cycle flux and oxidative phosphorylation. Conversely, inhibition of heme export reduces heme
synthesis and promotes the TCA cycle fueling and flux as well as oxidative phosphorylation. These data indi-
cate that the heme synthesis-export systemmodulates the TCA cycle and oxidative metabolism and provide
a mechanistic basis for the observation that both processes are enhanced in cells with high-energy demand.INTRODUCTION
Heme is an iron-containing porphyrin of vital importance for cells
because of its involvement in several biological processes
(Chiabrando et al., 2014). Heme can be acquired from dietary
sources, but it is also synthetized directly by cells. Heme synthe-
sis consists of eight enzymatic reactions that start in mitochon-
dria with the condensation of succinyl-coenzyme A (CoA) with
glycine to form 5-aminolevulinic acid (ALA). This reaction is cata-
lyzed by 5-aminolevulinate synthase (ALAS), the rate-limiting
enzyme of the heme synthetic pathway. Two genes encode the
ALAS enzyme, ALAS1, which is ubiquitously expressed, and
ALAS2, which is specific for the erythroid lineage. Together
with endogenous biosynthesis, cellular heme homeostasis relies
on the balanced and coordinated expression/activity of en-
zymes, transporters, and accessory proteins involved in extra-
cellular heme import, heme incorporation into hemoproteins,
heme degradation, and heme export from the cytosol to theThis is an open access article under the CC BY-Nextracellular space. This latter activity ismediated by the cell sur-
face feline leukemia virus subgroup C receptor 1a (FLVCR1a),
one of the two proteins encoded by the FLVCR1 gene (Quigley
et al., 2004; Khan and Quigley, 2011; Chiabrando et al., 2012).
Heme has profound and complex implications in processes
related to cell energy production. Indeed, heme is involved in ox-
ygen transport and has pivotal functions inmitochondria, serving
as a cofactor for most of the respiratory chain complexes (Kim
et al., 2012) and interacting with the translocases responsible
for the ADP/ATP exchange between mitochondria and cytosol
(Azuma et al., 2008; Sabová et al., 1993; Giraud et al., 1998).
Moreover, heme biosynthesis is considered a cataplerotic
pathway for the tricarboxylic acid (TCA) cycle, as the process
consumes succinyl-CoA, an intermediate of the TCA cycle
(Frezza et al., 2011; Fukuda et al., 2017). Finally, being one of
the major cellular iron-consuming activities, heme biosynthesis
competes with mitochondrial biogenesis of iron-sulfur (Fe-S)




OPEN ACCESSelectron transport chain (ETC) complexes and of some TCA cy-
cle enzymes.
The control of cell energy metabolism and of nutrient expendi-
ture to sustain energy production is particularly important in cells
under conditions of high-energy demand, such as during prolif-
eration. Therefore, it is not surprising that alterations in heme
metabolism are frequently observed in cancer (Fiorito et al.,
2020). It is commonly assumed that most tumors rely on high
heme synthesis by ALAS1. Likewise, increased expression of
the heme exporter FLVCR1a has been recently reported. How-
ever, the precise mechanisms underpinning enhanced heme
synthesis and enhanced heme export in tumors remain substan-
tially unexplored (Russo et al., 2019; Shen et al., 2018; Peng
et al., 2018). Experimental evidence suggests that heme synthe-
sis by ALAS1 and heme export by FLVCR1a are two highly coor-
dinated processes (Chiabrando et al., 2012; Vinchi et al., 2014,
Doty et al., 2015). However, the two processes have never
been studied reciprocally in the context of cancer, and their ef-
fect on the global regulation of cell energy metabolism has not
been explored in detail.
Here, we document that ALAS1-mediated heme synthesis and
FLVCR1a-mediated heme export are intertwined processes and
show that the heme synthesis-export axis is crucial for control-
ling the TCA cycle and oxidative phosphorylation (OXPHOS).
RESULTS
FLVCR1a-mediated heme export sustains heme
synthesis
Heme synthesis is mainly controlled by heme itself, through a
feedback inhibition on ALAS1 (Zheng et al., 2008; Kubota
et al., 2016; Srivastava et al., 1988; Lathrop and Timko, 1993).
Therefore, we hypothesized that the promotion of heme export
could be a strategy adopted by cells to avoid heme accumula-
tion and, in that way, ensure sustained heme synthesis. To test
that hypothesis, we chose as model systems the colorectal can-
cer (CRC) cell lines Caco2, C80, and SKCO1, in which we
silenced FLVCR1a using RNA interference (Figure S1).
We focused on CRC because a role for FLVCR1a in intestinal
cells was previously demonstrated (Fiorito et al., 2015). More-
over, we found that the FLVCR1 gene was overexpressed in
colorectal tumors, both in humans (Figures S2A and S2B) and
in mice (Figure S2C), suggesting an active heme efflux in these
cells. The relevance of FLVCR1a for CRC is also supported by
the observation that FLVCR1a-silenced Caco2 cells proliferated
more slowly (Figures S2D and S2E) and displayed a greater
extent of basal apoptosis (Figure S2F) than control cells did.
Similar to Caco2 cells, FLVCR1a silencing also led to increased
apoptosis in SKCO1 and C80 cells (Figures S2G and S2H). In line
with in vitro results, subcutaneous injection of FLVCR1a-
silenced SKCO1 cells in non-obese diabetic severe combined
immunodeficiency (NOD-SCID) gamma (NSG) mice gave rise
to smaller tumors than the tumors obtained by the injection of
control cells (Figure S2I), confirming the inhibitory effect of
FLVCR1a knockdown on CRC cell proliferation/survival in an
in vivo context as well.
To confirm the role of FLVCR1a as a heme exporter and to
assess its function in the control of de novo synthetized heme,2 Cell Reports 35, 109252, June 15, 2021we analyzed the extent and kinetics of heme export and synthe-
sis in CRC cell lines upon FLVCR1a silencing. In washout exper-
iments after treatment with the heme analog zinc-mesoporphyrin
(ZnMP), FLVCR1a-silenced Caco2 cells retained more ZnMP
than control cells did (Figure 1A), pointing to FLVCR1a as a
crucial mediator of heme efflux in those cells. Moreover, after in-
duction of heme biosynthesis by the heme precursor 5-aminole-
vulinic acid (5-ALA), FLVCR1a-silenced cells experienced a
faster and greater increase in the amount of intracellular heme
than control cells did. This accumulation was blunted by the
heme biosynthesis inhibitor succinylacetone (SA) (Figure 1B),
indicating that FLVCR1a prevents the accumulation of de novo
synthesized heme. We also analyzed the rate of heme synthesis
in FLVCR1a-silenced Caco2 cells, taking advantage of metabo-
lomic and tracing analyses. Among heme precursors, only 5-ALA
could be detected in the experimental conditions of our assays.
However, 5-ALA synthesis is the rate-limiting step in heme
biosynthesis, reflecting the progress of the entire process. By
measuring the intracellular production of 5-ALA, we observed
less 5-ALA in FLVCR1a-silenced Caco2 cells as compared
with that of controls (Figure 1C). In addition, in time-course
experiments, FLVCR1a-deficient Caco2 cells maintained in me-
dium with uniformly labeled glucose (U-13C-glucose) or gluta-
mine (U-13C-glutamine) showed reduced incorporation of
labeled carbons in 5-ALA (Figures 1D and 1E), confirming that
ALAS1 activity was reduced in those cells relative to controls.
These data strengthen the assumption that the FLVCR1a func-
tion is required to sustain heme synthesis. Consistent with data
obtained in Caco2 cells, we observed reduced ALAS1 expres-
sion in FLVCR1a-silenced SKCO1 and C80 cells (Figure S3).
Conversely, FLVCR1a overexpression in Caco2 cells resulted
in increased ALAS1 expression (Figure 1F).
These results indicate that, by prompting heme export,
FLVCR1a limits the feedback-inhibitory effect of accumulated
heme on ALAS1, thus favoring heme production. Hence, the
two processes of heme synthesis and heme export define a
unique system in which heme export is crucial to sustain heme
synthesis.
The heme synthesis-export system controls the
OXPHOS rate
Given the strong relationship between heme and cell energy pro-
duction, we sought to analyze the effect of the heme synthesis-
export axis on cellular energetic metabolism. To that end, we
evaluated mitochondrial function in FLVCR1a-silenced cells.
A significant enhancement in mitochondrial biogenesis was
detected upon FLVCR1a silencing (Figures 2A, S4A, and S4B),
indicating alterations in mitochondrial properties. FLVCR1a
silencing in Caco2 cells also resulted in increased activity in all
the complexes involved in the respiratory chain (Figure 2B),
including ATP synthase (Figure 2C). Increased OXPHOS in
FLVCR1a-silenced cells was supported by additional pieces of
evidence, such as increased mitochondrial membrane potential
(Figures 2D and S4C), mitochondrial basal calcium levels (Fig-
ure 2E), and mitochondrial ability to accumulate calcium upon
agonist stimulation (Figure 2F). Moreover, although FLVCR1a
depletion did not affect total cellular ATP levels (Figure S4D),
FLVCR1a-silenced cells showed significantly more ATP in the
Figure 1. The FLVCR1a-mediated heme export sustains heme synthesis
(A) Zinc-mesoporphyrin (ZnMP) retention in Caco2 cells treated with 5 mM ZnMP for 30 min (uptake phase) and fluorometrically analyzed 60 min after removal of
ZnMP from the medium (washout phase). The graph shows the percentage of retained ZnMP fluorescence at the end of the washout phase, with respect to the
fluorescence detected immediately after the uptake phase. FLVCR1a-silenced Caco2 cells are compared with cells expressing a scramble short hairpin RNA
(shRNA). Data represent means ± SEM, n = 2. For statistical analyses, an unpaired Student’s t test was used. *p < 0.05.
(B) Heme content in Caco2 cells treated with 5 mM 5-aminolevulinic acid (5-ALA;black bars and white bars) or with 5 mM 5-ALA + 0.5 mM succinylacetone (SA;
green outlined bars) for the indicated time points. FLVCR1a-silencedCaco2 cells are comparedwith cells expressing a scramble shRNA. Values are expressed as
relative fluorescence intensity. Data represent means ± SEM, n = 2. For statistical analyses, a two-way analysis of variance was used, followed by the Bonferroni
correction for multiple group comparisons. **p < 0.01, ***p < 0.001.
(C) Intracellular 5-ALA levels. FLVCR1a-silenced Caco2 cells are compared with cells expressing a scramble shRNA. Values are expressed as peak area/mg
proteins. Data represent means ± SEM of n = 4 wells pooled from two independent experiments. For statistical analyses, an unpaired Student’s t test was used.
**p < 0.01.
(D and E) Accumulation of 13C2-5-ALA in cells incubated with U-
13C-glucose (D) or of 13C3-5-ALA in cells incubated with U-
13C-glutamine (E) for the indicated
time. FLVCR1a-silenced Caco2 cells are compared with cells expressing a scramble shRNA. Values are expressed as peak area/mg proteins. Data represent
means ± SEM of n = 4 wells pooled from two independent experiments. For statistical analyses, a two-way analysis of variance was used, followed by the
Bonferroni correction for multiple group comparisons. ***p < 0.001.
(F) Western blot analysis of ALAS1 expression in Caco2 cells. Cells overexpressing FLVCR1a (indicated as FLVCR1a+) are compared with cells stably transduced
with an empty vector. Vinculin expression is shown as a loading control. Band intensities were measured by densitometry and were normalized to vinculin
expression. Densitometry data represent means ±SEM, n = 2. For statistical analyses, an unpaired Student’s t test was used. *p < 0.05. Data are representative of
three independent experiments.
See also Figures S1–S3.
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OPEN ACCESSmitochondria (Figures 2G, S4E, and S4F) than control cells did.
Remarkably, we also measured less ATP in the cytosol of
FLVCR1a-silenced cells (Figure 2H), indicating ATP retention in
the mitochondria. This conclusion is supported by the finding
that FLVCR1a knockdown led to reduced activity of adenine
nucleotide translocases (ANTs) (Figure 2I).
ETC complexes II, III, and IV exploit heme as a cofactor. The
role of heme in complex II is still undetermined and likely unre-
lated to electron transport (Rutter et al., 2010; Kim et al., 2012).
Conversely, heme is crucial to the function of complexes III
and IV (Kim et al., 2012). The data described above show that
FLVCR1a silencing is associatedwith decreased heme synthesis
by ALAS1 and with enhanced OXPHOS, suggesting that the
amount of heme provided by the residual ALAS1-dependent
production is sufficient to sustain the activity of ETC complexes
III and IV. In line with that conclusion, we detected reduced com-
plex III and IV activity, as well as decreased ATP production, in
ALAS1-silenced cells (Figures S4G and S4H), in which heme
production is expected to be strongly compromised.
Conversely, congruent with that observed in FLVCR1a-silenced
cells, the activity of complexes I and II was enhanced upon
ALAS1 knockdown (Figure S4G).Figure 2. The heme synthesis-export system controls the OXPHOS ra
(A) Mitochondrial biogenesis expressed as a ratio between the expression of them
the expression of the nuclear DNA-encoded mitochondrial protein SDH-A (the 70
with cells expressing a scramble shRNA. Data represent means ± SEM, n = 6. F
(B) Activities of themitochondrial electron transport chain complexes I–IV. FLVCR1
Results were expressed as nmol of NAD+/min/mg of mitochondrial protein for c
complexes II–III, and nmol of oxidized cytochrome c/min/mg of mitochondrial prot
an unpaired Student’s t test was used. *p < 0.05, **p < 0.01.
(C) ATPmeasurements using a luciferase-basedmethod in FLVCR1a-silencedCa
of mitochondrial ATP over the basal ATP levels, upon stimulation of ATP synthesis
on basal mitochondrial ATP levels (plateau I) and data on mitochondrial ATP leve
reported in Figure S4E. The accumulation of ATP was computed as plateau I  p
independent experiments. For statistical analyses, an unpaired Student’s t test w
(D) Mitochondrial membrane potential measured by the JC-1 fluorescent dye-bas
a scramble shRNA. Data represent means ± SEM, n = 6 coverslips pooled from th
test was used. ***p < 0.001.
(E) Resting mitochondrial calcium levels. FLVCR1a-silenced Caco2 cells are comp
n = 6 coverslips pooled from three independent experiments. For statistical anal
(F) Mitochondrial calcium uptakemeasured as Ca2+ responses to an agonist stimu
the graph showing quantification of mitochondrial Ca2+ from three independent ex
expressing a scramble shRNA. Data represent means ± SEM, n = 14 coverslips po
Student’s t test was used. *p < 0.05.
(G) Basal mitochondrial ATP levels measured using a luciferase probe targeted t
cells expressing a scramble shRNA. Data are referred to three independent ex
independent experiments. For statistical analyses, an unpaired Student’s t test w
(H) Basal cytosolic ATP levels measured using a luciferase probe targeted to the
scramble shRNA. Data represent means ± SEM, n = 20 coverslips pooled from th
test was used. **p < 0.01.
(I) Adenine nucleotide translocases (ANTs) activity. Results are expressed as mm
cells are compared with cells expressing a scramble shRNA. Data represent m
used. **p < 0.01.
(J) Activities of the mitochondrial electron transport chain complexes I–IV in Caco
stably transduced with an empty vector. Results were expressed as nmol NAD+/m
min/mg of mitochondrial protein for complexes II–III, and nmol oxidized cytochro
SEM, n = 3. For statistical analyses, an unpaired Student’s t test was used. *p <
(K)Mitochondrial ATP levelsmeasured by a bioluminescent assay kit in Caco2 cell
transduced with an empty vector. Results are expressed as nmol/mg of mitochon
unpaired Student’s t test was used. *p < 0.05.
See also Figures S4 and S5.The increased ETC complexes activity and mitochondrial ATP
levels observed in FLVCR1a-silenced Caco2 cells were
confirmed in SKCO1 (Figures S4I and S4J) andC80 cells (Figures
S4K and S4L). In a complementary perspective, FLVCR1a-over-
expressing cells showed the opposite phenotype, with a signifi-
cant reduction in the activity of all the ETC complexes and the
mitochondrial ATP levels (Figures 2J and 2K).
Interestingly, the ETC complexes activities returned to base-
line levels in FLVCR1a-silenced Caco2 cells (Figure S5A) upon
short-term serum withdrawal, indicating that the heme synthe-
sis-export system is required to keep downOXPHOS under con-
ditions of serum stimulation. Consistently, after serum starvation
in FLVCR1a-silenced cells, ATP levels decreased (Figure S5B),
and the oxygen consumption rate (OCR) was comparable with
that detected in control cells (Figure S5C). Thus, the rate of OX-
PHOS controlled by the heme synthesis-export system is influ-
enced by environmental conditions. Notably, a surplus of ATP
was still present in FLVCR1a-silenced cells as compared with
that of controls upon serum starvation (Figure S5B), confirming
that mitochondrial ATP overload in FLVCR1a-silenced cells is
partly dependent on mitochondrial ATP retention, rather than
solely on increased ATP production.te
itochondrial DNA-encoded protein COX-I (the subunit I of ETC complex IV) and
-kDa subunit of ETC complex II). FLVCR1a-silenced Caco2 cells are compared
or statistical analyses, an unpaired Student’s t test was used. ***p < 0.001.
a-silenced Caco2 cells are comparedwith cells expressing a scramble shRNA.
omplex I, nmol of reduced cytochrome c/min/mg of mitochondrial protein for
ein for complex IV. Data represent means ±SEM, n = 3. For statistical analyses,
co2 cells comparedwith cells expressing a scramble shRNA. The accumulation
, is shown. The measure is considered a readout of ATP synthase activity. Data
ls upon ATP synthesis stimulation with a Ca2+-dependent agent (plateau II) are
lateau II. Data represent means ± SEM of n = 20 coverslips pooled from three
as used. *p < 0.05.
ed method. FLVCR1a-silenced Caco2 cells are compared with cells expressing
ree independent experiments. For statistical analyses, an unpaired Student’s t
ared with cells expressing a scramble shRNA. Data represent means ± SEM of
yses, an unpaired Student’s t test was used. *p < 0.05.
lation (100 mMATP). Representative traces of Ca2+ responses are shown. Next,
periments is reported. FLVCR1a-silenced Caco2 cells are compared with cells
oled from three independent experiments. For statistical analyses, an unpaired
o the mitochondrial matrix. FLVCR1a-silenced Caco2 cells are compared with
periments and represent means ± SEM, n = 20 coverslips pooled from three
as used. ***p < 0.001.
cytosol. FLVCR1a-silenced Caco2 cells are compared with cells expressing a
ree independent experiments. For statistical analyses, an unpaired Student’s t
oles exchanged ATP/mg of mitochondrial proteins. FLVCR1a-silenced Caco2
eans ± SEM, n = 3. For statistical analyses, an unpaired Student’s t test was
2 cells overexpressing FLVCR1a (indicated as FLVCR1a+) compared with cells
in/mg of mitochondrial protein for complex I, nmol of reduced cytochrome c/
me c/min/mg of mitochondrial protein for complex IV. Data represent means ±
0.05, **p < 0.01.
s overexpressing FLVCR1a (indicated as FLVCR1a+) comparedwith cells stably
drial proteins. Data represent means ± SEM, n = 3. For statistical analyses, an
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OPEN ACCESSCollectively, data indicate that the heme synthesis-export sys-
tem is required to maintain a low rate of OXPHOS and proper
ATP distribution between the mitochondria and the cytosol.
The heme synthesis-export system controls the TCA
cycle flux
OXPHOS is sustained by the TCA cycle, and heme synthesis
participates in TCA cycle cataplerosis. Accordingly, we exam-
ined metabolic differences in the TCA cycle in FLVCR1a-defi-
cient versus FLVCR1a-proficient Caco2 cells. The total flux of
the TCA cycle was significantly upregulated in FLVCR1a-
silenced cells compared with controls (Figure 3A, see the his-
togram in the center), and several TCA-cycle enzymes,
including citrate synthase, a-ketoglutarate dehydrogenase,
succinate dehydrogenase, and malate dehydrogenase (Fig-
ure 3A), displayed enhanced activity after FLVCR1a knock-
down. Increased TCA cycle flux upon FLVCR1a silencing
was confirmed in SKCO1 and C80 cells (Figures S6A and
S6B).
We also evaluated the levels of the TCA-cycle intermediates
in FLVCR1a-silenced cells, both at steady-state conditions (Fig-
ure 3A) and in time-course experiments with cells cultured in
medium containing U-13C-glucose or U-13C-glutamine (Fig-
ure 4). Under steady-state conditions, complex modulation of
TCA-cycle metabolite levels was observed. Indeed, the amount
of some intermediates (citrate and cis-aconitate) was greater in
FLVCR1a-silenced cells than it was in controls, in line with the
increased activity of the enzymes involved in their production
(citrate synthase and aconitase). In contrast, the levels of other
intermediates (oxaloacetate and succinate) were reduced (Fig-
ure 3A). Time-course experiments revealed that incorporation
of labeled carbons from U-13C-glucose in citrate, a-ketogluta-
rate, and malate was enhanced in FLVCR1a-silenced cells, indi-
cating faster consumption of labeled glucose in those cells than
in the controls (Figure 4B). Similar results were obtained upon
U-13C-glutamine administration (Figure 4C). Interestingly, in
FLVCR1a-silenced cells maintained in U-13C-glutamine, the
appearance of both citrate 13C4 and
13C5 isotopologues was
enhanced (Figure 4C), indicating that FLVCR1a silencing stimu-
lates both oxidative and reductive glutamine metabolism. The
combined increase of both TCA-cycle flux and reductiveFigure 3. The heme synthesis-export system controls the TCA cycle fl
(A) FLVCR1a-silenced Caco2 cells are compared with cells expressing a scramble
as pmol CO2/h/mg of protein. Data represent means ±SEM, n = 3. For statistical an
enzymes activities are reported in boxes and are expressed as mU/mg of mitocho
unpaired Student’s t test was used. *p < 0.05, ***p < 0.001. Finally, TCA cycle met
proteins. Oxaloacetate levels are expressed as mmol/mg of proteins. Data repres
Welch’s correction was used for all the metabolites except oxaloacetate. *p < 0.
(B) TCA-cycle flux in Caco2 cells expressing a scramble shRNA untreated or tre
FLVCR1a-silenced Caco2 cells is reported for comparison. Results are expres
statistical analyses, an unpaired Student’s t test was used to compare the two m
(C) TCA-cycle flux in Caco2 cells, in which the expression of ALAS1 was downre
expressing a scramble shRNA. Results are expressed as pmol CO2/h/mg of prot
Student’s t test was used. *p < 0.05, **p < 0.01.
(D) TCA-cycle flux in Caco2 cells overexpressing FLVCR1a (indicated as FLVCR1
the TCA-cycle flux of FLVCR1a-overexpressingCaco2 cells treatedwith 25 mMof h
mg of protein. Data represent means ± SEM, n = 3. For statistical analyses, an unp
**p < 0.01.
See also Figure S6.carboxylation likely explains the heterogeneous modulation of
TCA-cycle intermediates levels detected at steady-state
conditions.
The TCA cycle is intended to produce both metabolites and
reducing equivalents to support OXPHOS. Interestingly,
FLVCR1a silencing did not alter the expression of nicotin-
amide phosphoribosyltransferase (Figure S6C), the main nico-
tinamide adenine dinucleotide (NAD)-biosynthetic enzymes
(NBEs), commonly regulated during tumor metabolic reprog-
ramming (Audrito et al., 2018). Moreover, expression of the
other NBEs was only modestly affected by FLVCR1a knock-
down (Figure S6C), with negligible effects on NAD+ and
NADH levels (Figure S6D). Accordingly, the NAD+/NADH ratio
was preserved (Figure S6E), indicating that FLVCR1a loss
does not affect the levels of those coenzymes. The combined
enhancement of both the TCA-cycle flux and OXPHOS prob-
ably accounts for the preserved NAD+/NADH ratio observed in
FLVCR1a-silenced cells.
Our data suggest that FLVCR1a controls the TCA cycle by
modulating the intracellular heme pool involved in ALAS1 inhibi-
tion. Consistently, hemin administration in control Caco2 cells
to induce feedback reduction of ALAS1 activity led to increased
TCA-cycle flux, mimicking the effects of decreased heme
export in FLVCR1a-silenced cells (Figure 3B). Moreover, we
observed an increased TCA-cycle flux in ALAS1-silenced
Caco2 cells (Figures 3C and S6F), similar to that reported for
FLVCR1a-silenced cells. Conversely, FLVCR1a-overexpressing
cells showed the opposite phenotype, with a significant reduc-
tion in the TCA-cycle flux, which could be reverted by treatment
with hemin or with the heme synthesis inhibitor, SA (Figure 3D).
Together, these findings strengthen the notion that FLVCR1a
controls the TCA-cycle flux by modulating the rate of heme syn-
thesis. The overall dataset indicates that FLVCR1a participates
to the regulation of ALAS1 activity by modulating intracellular
heme accumulation, with implications for the control of the
TCA-cycle flux.
The heme synthesis-export system controls TCA-cycle
fueling
The TCA cycle is a central hub for cell metabolic pathways. Me-
tabolomic studies in Caco2 cells revealed a dramatic change inux: Metabolic analyses at steady-state conditions
shRNA. TCA-cycle flux is reported in the center of the figure and is expressed
alyses, an unpaired Student’s t test was used. **p < 0.01.Moreover, TCA-cycle
ndrial proteins. Data represent means ± SEM, n = 3. For statistical analyses, an
abolite levels, except oxaloacetate, are shown and are expressed as mmol/g of
ent mean ± SEM of n = 3 wells. For statistical analyses, an unpaired t test with
05. For oxaloacetate, an unpaired Student’s t test was used. **p < 0.01.
ated with 25 mM of hemin for 2 h. Moreover, the TCA-cycle flux of untreated
sed as pmol CO2/h/mg of protein. Data represent means ± SEM, n = 3. For
atched groups. *p < 0.05, ***p < 0.001.
gulated using two specific shRNAs (ALAS1 and ALAS12), compared with cells
ein. Data represent means ± SEM, n = 3. For statistical analyses, an unpaired
a+) are compared with cells stably transduced with an empty vector. Moreover,
emin or 0.5mMof SA for 2 h is reported. Results are expressed as pmol CO2/h/
aired Student’s t test was used to compare the twomatched groups. *p < 0.05,
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OPEN ACCESSthe profile of cell metabolites upon FLVCR1a silencing (Fig-
ure 5A), suggesting alterations in several metabolic reactions.
Therefore, alterations in metabolites or metabolic pathways in-
terlinked with the TCA cycle were explored.
Pyruvate levels were lower in FLVCR1a-silenced cells than
they were in controls (Figure 5B), but that reduction could not
be ascribed to defects in pyruvate production by the glycolytic
pathway. Indeed, incorporation of labeled carbons in pyruvate
from U-13C-glucose was enhanced in FLVCR1a-silenced cells
(Figure 5C), indicating increased glycolysis. Concomitantly, aer-
obic glycolysis was promoted, as demonstrated by high lactate
production in FLVCR1a-silenced cells (Figure 5D). Furthermore,
upon U-13C-glucose administration, the amount of citrate 13C2
and 13C3 isotopologues (readouts of pyruvate dehydrogenase
[PDH] and pyruvate carboxylase [PC] contribution to the TCA cy-
cle, respectively) was higher in FLVCR1a-silenced cells than in
controls (Figures 5E and 5F). These data indicate that, in addition
to lactate dehydrogenase (LDH), both PDH and PC enzymes
strongly consume pyruvate to sustain the TCA cycle in
FLVCR1a-silenced cells and that TCA-cycle fueling by glucose
is enhanced in FLVCR1a-silenced cells.
Additional pathways were then analyzed. Increased fatty
acid b-oxidation was detected in FLVCR1a-silenced cells
(Figure 5G). However, ketogenesis was also enhanced, as
demonstrated by the higher amount of b-hydroxy-b-methylglu-
taryl-CoA (HMG-CoA) and b-hydroxybutyrate (b-OH-butyrate)
(Figure 5H). Because ketogenesis consumes the acetyl-CoA
produced by fatty acids b-oxidation, the data suggest that
the surplus of fatty acid b-oxidation detected in FLVCR1a-
silenced cells provides a poor contribution to TCA-cycle
fueling. Conversely, tracing analyses of FLVCR1a-silenced
cells with U-13C-glutamine showed enhanced incorporation
of labeled carbons in glutamate (Figure 6A) and, as stated pre-
viously, in a-ketoglutarate (Figure 4C), indicating increased glu-
taminolysis. That conclusion was supported by the detection of
greater glutaminase (GLS) and less glutamine synthetase
(GLUL) activity in FLVCR1a-silenced Caco2 cells than found
in controls (Figure 6B). These results, together with those illus-
trating enhanced oxidation/reductive carboxylation of gluta-
mine, attest to increased TCA-cycle fueling by glutamine in
FLVCR1a-silenced cells.
Finally, when comparedwith controls, FLVCR1a-silenced cells
showed reduced total g-aminobutyric acid (GABA) levels (Fig-
ure 6C) and increased incorporation of labeled carbons fromFigure 4. The heme synthesis-export system controls the TCA cycle fl
cells compared with cells expressing a scramble shRNA
(A) Predicted labeling pattern of the indicatedmetabolites in cells cultured with U-1
carbon units, respectively. Orange circles indicate 13C carbon units derived from U
carbon units derived from U-13C-glucose are depicted in blue. Green circles
carboxylation occurs, the 13C carbon units derived from U-13C-glutamine are repr
(B) Accumulation of 13C2-citrate,
13C2-a-ketoglutarate, and
13C2-malate in cells
SEM, n = 4 wells pooled from two independent experiments. For statistical an
correction for multiple group comparisons. *p < 0.05, **p < 0.01, ***p < 0.001.
(C) Accumulation of 13C4-citrate,
13C5-a-ketoglutarate and
13C4-malate in ce
13C5-citrate derived from reductive carboxylation (violet arrow) is reported in
independent experiments. For statistical analyses, a two-way analysis of va
comparisons. *p < 0.05, **p < 0.01, ***p < 0.001.U-13C-glucose or U-13C-glutamine into succinate semialdehyde
(SSA) (Figures 6D and 6E), an intermediate produced when
GABA is converted by GABA transaminase into succinate
through the GABA shunt. Together, these results indicate
increased TCA-cycle anaplerosis by GABA.
Overall, reduced heme synthesis-export results in the promo-
tion of the TCA cycle and in the recruitment of several pathways
to sustain it, with consequences on the rate of OXPHOS.
Relevance of the heme synthesis-export system in vivo
Mining of the BioXpress database (Wan et al., 2015) revealed
overexpression of FLVCR1 in several tumor types other than
CRC (Figure 7A), suggesting that the ALAS1-FLVCR1a system
could be exploited to modulate oxidative metabolism in different
tumor contexts. To address that point, we down-modulated
FLVCR1a in neuroblastoma SH-SY5Y cells (Figures S7A and
S7B) and in tumor endothelial cells (BTECs, breast-cancer-
derived tumor endothelial cells) (Figures S7C and S7D). We
chose such models based on previous observations that
FLVCR1 inactivation leads to reduced survival/proliferation in
the nervous and endothelial system (Chiabrando et al., 2016;
Petrillo et al., 2018; Bertino et al., 2019).
In SH-SY5Y cells, FLVCR1a silencing resulted in greater heme
accumulation than controls upon stimulation of de novo heme
biosynthesis (Figure S7E); in BTECs, increased heme levels
were already detectable at the steady state after FLVCR1a
knockdown (Figure S7F), indicating that, in these cell lines,
FLVCR1a down-modulation also blocks heme efflux. Moreover,
in both FLVCR1a-silenced cell lines, we observed enhanced ac-
tivity of ETC complexes with increased mitochondrial ATP levels
(Figures 7B, 7C, S7G, and S7H) as well as increased TCA-cycle
flux (Figures 7D and S7I), confirming the observations obtained
in the CRC cell lines.
Finally, to evaluate the in vivo relevance of our findings, we
took advantage of tamoxifen-inducible endothelial-specific
Flvcr1a-null mice (Flvcr1afl/fl;Cdh5(PAC)-CreERT2) (Figure 7E)
and analyzed oxidative metabolism in tumor endothelial cells
(TECs) isolated from subcutaneous tumors. As observed
in vitro and in Flvcr1a-deleted endothelial cells (indicated as
Flvcr1a-KO), the activity of TCA-cycle enzymes (Figure 7F) and
that of ETC complexes and the levels of mitochondrial ATP (Fig-
ures 7G and 7H) were higher than in control counterparts. These
data support the notion that FLVCR1a-mediated heme export
modulates TCA cycle and OXPHOS.ux: Time-course metabolic analyses, with FLVCR1a-silenced Caco2
3C-glucose or U-13C-glutamine. Colored and black circles indicate 13C and 12C
-13C-glucose. When pyruvate carboxylase (PC) catalyzes the reaction, the 13C
indicate 13C carbon units derived from U-13C-glutamine. When reductive
esented in violet. PDH, pyruvate dehydrogenase; LDH, lactate dehydrogenase.
incubated with U-13C-glucose for the indicated time. Data represent means ±
alyses, a two-way analysis of variance was used, followed by the Bonferroni
lls incubated with U-13C-glutamine for the indicated time. Accumulation of
the violet box. Data represent means ± SEM, n = 4 wells pooled from two
riance was used, followed by the Bonferroni correction for multiple group
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The results described here illustrate the functionality of a heme
synthesis-export axis adopted by cells to reduce the TCA-cycle
flux and its fueling with the ensuing reduction of OXPHOS.
Previous work from our laboratory has demonstrated that
there is a strong relationship between heme synthesis and
heme export, whereby the pool of newly synthetized heme is
controlled by the concerted actions of the heme synthetic
enzyme ALAS1 and the heme exporter FLVCR1a. For example,
in hepatic cells from liver-specific Flvcr1a-null mice, reduced
ALAS1 activity was detected (Vinchi et al., 2014). Moreover, liver
cells from wild-type mice displayed co-regulation of Alas1 and
Flvcr1 gene expression in response to 5-ALA (Vinchi et al.,
2014). Similarly, FLVCR1b-overexpressing HeLa cells exhibited
more mRNA for several heme biosynthetic enzymes and an
increased heme content, which could be prevented by treatment
with the heme synthesis inhibitor SA (Chiabrando et al., 2012),
indicating increased heme synthesis when heme export is
enhanced. Data presented in this work confirm the relationship
between heme production and export and provide evidence
that the heme synthesis-export system critically contributes to
TCA-cycle flux and OXPHOS.
Results from several studies have documented that ALAS1,
the rate limiting enzyme of the heme biosynthetic pathway, is
negatively regulated by heme itself (Zheng et al., 2008; Kubota
et al., 2016; Srivastava et al., 1988; Lathrop and Timko, 1993).
Heme controls transcription (Yamamoto et al., 1982), translation
(Sassa and Granick, 1970; Yamamoto et al., 1983), and stability
(Hamilton et al., 1991) of ALAS1mRNA. Moreover, heme binding
to heme regulatory motifs, situated in themitochondrial targeting
sequence of ALAS1, inhibits protein translocation to the mito-
chondria (Yamauchi et al., 1980). We found that FLVCR1a-medi-
ated heme export introduces a further level of regulation by
controlling the size of the regulatory heme pool responsible for
ALAS1 modulation.
The observed enhancement of heme synthesis associated
with reduced activity of ETC complexes, which exploit heme
as a co-factor, is counterintuitive. Moreover, our data are in
apparent contrast to other studies showing that the administra-
tion of exogenous heme promotes ETC activity (Vandekeere
et al., 2018). Our finding that the administration of exogenous
heme phenocopied FLVCR1a and ALAS1 silencing, leading to
increased TCA-cycle flux, which, in turn, supports the activity
of ETC complexes, provides an alternative explanation forFigure 5. The heme synthesis-export system controls the TCA-cycle f
compared with cells expressing a scramble shRNA
(A) Heatmap representation of metabolome profiles analyzed by hierarchical clu
(B) Pyruvate levels. Values are expressed as mmol/g of proteins. Data represent
Welch’s correction was used. *p < 0.05.




represent means ±SEM, n = 4wells pooled from two independent experiments. Fo
Bonferroni correction for multiple group comparisons. **p < 0.01, ***p < 0.001.
(G) Fatty acids b-oxidation. Values are expressed as pmol of 14C-acid soluble m
wells. For statistical analyses, an unpaired Student’s t test was used. *p < 0.05.
(H) b-hydroxy-b-methylglutaryl-CoA (HMG-CoA) and b-hydroxybutyrate (b-OH-b
cellular proteins, respectively. Themeasure of the twometabolites was considered
statistical analyses, for HMG-CoA an unpaired t test with Welch’s correction wassuch seemingly discrepant observations. Moreover, when
comparing the effects of FLVCR1a silencing versus ALAS1
silencing on the activity of ETC complexes, the FLVCR1a-
controlled heme pool appears to regulate cellular respiration
indirectly through the TCA cycle and not directly by regulating
heme supply to ETC complexes.
The modulation of the TCA cycle by the heme synthesis-
export axis might be explained by ALAS1-mediated TCA-cycle
cataplerosis, a process whose importance is also supported
by literature data: experimental models of hereditary leiomyoma-
tosis and renal-cell cancer, which bear inactivating mutation in
fumarate hydratase, show increased heme synthesis and
dependence on the heme-degrading enzyme HMOX-1 for sur-
vival (Frezza et al., 2011).
In addition to cataplerosis, other heme-controlled events may
contribute to the modulation of the TCA cycle. We found that
TCA-cycle fueling, by both glucose and glutamine, is enhanced
when the heme synthesis-export axis is inhibited. This is in
agreement with data showing heme-dependent control of
PDH, a key enzyme for supply of the TCA cycle by glucose
(Lynch et al., 2019) and with the observation that the heme-regu-
lated transcription factor BTB and CNC homology 1 (BACH1)
modulates the expression of the glycolytic enzymes hexokinase
2 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(Wiel et al., 2019) and the activity of PDH (Lee et al., 2019).
Altogether, these data suggest that heme efflux by FLVCR1a
finely tunes the rate of heme synthesis required for TCA-cycle
cataplerosis and for the establishment of a regulatory heme
pool that participates in the transcriptional regulation of genes
involved in TCA fueling. The induction of the heme synthesis-
export system represents a strategy adopted by cells to shut
down oxidative metabolism and ensure adequate heme supply
for hemoproteins’ production.
Metabolic alterations promoted by FLVCR1a silencing in CRC
cell lines were associated with reduced proliferation and
increased apoptosis. Similarly, FLVCR1a down-modulation in
synovial sarcoma cells (Peng et al., 2018) and in other trans-
formed cell lines (Chiabrando et al., 2016; Mercurio et al.,
2015) led to impaired proliferation/survival. Moreover, FLVCR1a
is overexpressed in several cancer types, and accumulating ev-
idence points to an essential role for heme synthesis in cancer
(Fiorito et al., 2020). Increased heme synthesis in tumors versus
healthy tissues is exploited for tumor fluorescence-guided sur-
gery (FGS) and to kill cancer cells by photodynamic therapy
(PDT) (Malik and Lugaci, 1987; Kennedy et al., 1990; Pengueling: Glucose and fatty acids, with FLVCR1a-silenced Caco2 cells
stering analysis, n = 3 wells.
means ± SEM of n = 3 wells. For statistical analyses, an unpaired t test with
3-citrate (F) in cells incubated with U-
13C-glucose for the indicated time. Data
r statistical analyses, a two-way analysis of variance was used, followed by the
etabolites (14C-ASM)/h/mg of proteins. Data represent means ± SEM of n = 3
utyrate) levels expressed as mmoles/mg of cellular proteins and mmoles/g of
as an index of ketone bodies amount. Data represent means ±SEM, n = 3. For
used, and for b-OH-butyrate, an unpaired Student’s t test was used. *p < 0.05.
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Figure 6. The heme synthesis-export system controls the
TCA cycle fueling: Glutamine and GABA, with FLVCR1a-
silenced Caco2 cells compared with cells expressing a
scramble shRNA
(A) Accumulation of 13C5-glutamate in cells incubated with U-
13C-
glutamine for the indicated time. Values are expressed as peak
area/mg of proteins. Data represent means ± SEM of n = 4 wells
pooled from two independent experiments. For statistical analyses,
a two-way analysis of variancewas used, followed by the Bonferroni
correction for multiple group comparisons. *p < 0.05, **p < 0.01.
(B) Glutaminase (GLS) and glutamine synthetase (GLUL) activities
are reported in gray background boxes and are expressed as
mmol of NADH/min/mg cellular proteins or mU/mg of cellular
proteins, respectively. Data represent means ± SEM, n = 3. For
statistical analyses, an unpaired Student’s t test was used. *p <
0.05, **p < 0.01.
(C) g-aminobutyric acid (GABA) levels expressed as mmol/g of
proteins. Data represent means ± SEM of n = 3 wells. For sta-
tistical analyses, an unpaired t test with Welch’s correction was
used. **p < 0.01.
(D and E) Accumulation of 13C2-succinate semialdehyde (
13C2-
SSA) in cells incubated with U-13C-glucose (D) or of 13C4-SSA in
cells incubated with U-13C-glutamine (E) for the indicated time.
Values are expressed as peak area/mg of proteins. Data represent
means ± SEM of n = 4 wells pooled from two independent ex-
periments. For statistical analyses, a two-way analysis of variance
was used, followed by the Bonferroni correction for multiple group
comparisons. *p < 0.05, **p < 0.01, ***p < 0.001.
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OPEN ACCESSet al., 1992). The growth-inhibitory effects of FLVCR1 knock-
down could be ascribed to its effect on the heme synthesis-
export axis, leading to the forced implementation of oxidative
metabolism and the compensatory engagement of several path-
ways to sustain the TCA cycle. Several other factors might also
contribute to reduced cell viability after FLVCR1a inactivation.
Heme synthesis is required to sustain the expression/activity of
several hemoproteins crucial for survival and proliferation,
including cyclooxygenases, catalases, peroxidases among
others (Chiabrando et al., 2014); in addition, dysregulated
heme metabolism promotes oxidative stress responsible for
DNA, lipid, and protein damage (Chiabrando et al., 2014).
We show here that Flvcr1a loss in endothelial cells in vivo re-
sults in enhanced TCA-cycle flux andOXPHOS, similar to that re-
ported for cultured endothelial cells and cancer cell lines.
Because endothelial cellsmainly rely on aerobic glycolysis for en-
ergy supply, these data indicate that they depend on the heme
synthesis-export axis to repress oxidative metabolism. More-
over, FLVCR1a silencing in endothelial cells reduces prolifera-
tion/survival, in linewithprevious findingsdocumentingabnormal
vascular development and embryo lethality inmicewith constitu-
tive Flvcr1a loss in the endothelium (Petrillo et al., 2018). We can,
therefore, speculate that themetabolic adaptation modulated by
the heme synthesis-export axis contributes to sustaining prolifer-
ation/survival, not only in tumor cells but also in endothelial cells.
A crucial role for FLVCR1a in proliferating cells is also supported
by the observation that mice with intestine-specific Flvcr1a
knockout display reduced proliferation of intestinal mucosa cellsFigure 7. Relevance of the heme synthesis-export system in vivo
(A) Frequency (%) of patient tumors with overexpression of FLVCR1 compared w
patients showing tumor FLVCR1 overexpression relative to the total number of pa
2015). For statistical analyses, a binomial test was used, with the null hypothesis b
patient. p < 0.01 was regarded as significant; *p < 0.01 (in all significant cases in w
than expected in the null hypothesis). #p < 0.01 (in all significant cases in which
expected in the null hypothesis).
(B) Activities of the mitochondrial electron transport chain complexes I–IV in FL
Results were expressed as nmol NAD+/min/mg of mitochondrial protein for com
plexes II–III, AND nmol oxidized cytochrome c/min/mg of mitochondrial protein fo
unpaired Student’s t test was used. **p < 0.01, *p < 0.001.
(C) Mitochondrial ATP levels measured by a bioluminescent assay kit in FLVCR1a
are expressed as nmol/mg of mitochondrial proteins. Data represent means ± SE
0.05.
(D) TCA-cycle flux in FLVCR1a-silenced BTECs compared with cells expressing
represent means ± SEM, n = 3. For statistical analyses, an unpaired Student’s t
(E) Polymerase chain reaction (PCR) on Flvcr1afl/fl;Cdh5(PAC)-CreERT2 mice and
distinction of the wild-type (242 bp), floxed (280 bp), and null allele (320 bp) of Flv
gives rise to a band referred to as the ‘‘null allele.’’
(F) TCA-cycle enzymes activities are reported in boxes and expressed as mU/m
cutaneous tumors in tamoxifen-inducible endothelial specific Flvcr1a null mice (Fl
isolated by subcutaneous tumors in control Flvcr1afl/fl mice. Data represent means
test was used. *p < 0.05.
(G) Activities of the mitochondrial electron transport chain complexes I–IV in TEC
Flvcr1a-null mice (Flvcr1afl/fl;Cdh5(PAC)-CreERT2 indicated as Flvcr1a-KO) are com
Results were expressed as nmol NAD+/min/mg of mitochondrial protein for com
plexes II–III, and nmol oxidized cytochrome c/min/mg of mitochondrial protein for
analyses, an unpaired Student’s t test was used. *p < 0.05, **p < 0.01.
(H) Mitochondrial ATP levels measured with a bioluminescent assay kit in TECs
Flvcr1a-null mice (Flvcr1afl/fl;Cdh5(PAC)-CreERT2 indicated as Flvcr1a-KO) are com
Results are expressed as nmol/mg of mitochondrial proteins. Data represent mean
t test was used. *p < 0.05.
See also Figure S7.
14 Cell Reports 35, 109252, June 15, 2021in physiological conditions and reduced survival upon experi-
mental induction of ulcerative colitis, a pathological state
requiring regeneration of the intestinal mucosa (Fiorito et al.,
2015). Moreover, the role of FLVCR1 in the maturation of
erythroid progenitors and in embryo development has been
extensively documented (Keel et al., 2008; Petrillo et al., 2018;
Doty et al., 2015; Mercurio et al., 2015). Altogether, these data
suggest that the metabolic rewiring regulated by the heme syn-
thesis-export system supports cell proliferation.
Heme synthesis is a constitutive process regulated at several
levels. Data in mice indicate that all cells need to export heme
through FLVCR1a, as evidenced by the embryonic lethal pheno-
type of animals with constitutive Flvcr1a loss and organ abnor-
malities in conditional models. This conclusion is also supported
by data in humans indicating that FLVCR1 gene mutations asso-
ciated to specific disorders do not completely abrogate the
heme efflux function, which attests to the hypomorphic nature
of suchmutations. Thus, we can speculate that the heme synthe-
sis-export system represents a physiological mechanism to
maintain heme homeostasis. Interestingly, FLVCR1 is induced
by hypoxia, strengthening the concept that the ALAS1-FLVCR1a
axis is required to shut down oxidative metabolism, an absolute
requirement when oxygen availability is limiting. Further studies
are required to better define the role of the heme synthesis-
export system in physiologic and pathologic conditions.
The TCA cycle is a central hub for cell energy metabolism, the
synthesis of macromolecules, and redox balance. Impaired
TCA-cycle functions are associated with a wide variety ofith their matched normal tissues across multiple cancer types. The number of
tients examined is indicated in the plot. Data derive from BioXpress (Wan et al.,
eing equal probability of FLVCR1 being up or downregulated in cancer for each
hich the number of patients with FLVCR1 overexpression is significantly greater
the number of patients with FLVCR1 overexpression is significantly less than
VCR1a-silenced BTECs compared with cells expressing a scramble shRNA.
plex I, nmol reduced cytochrome c/min/mg of mitochondrial protein for com-
r complex IV. Data represent means ± SEM, n = 3. For statistical analyses, an
-silenced BTECs compared with cells expressing a scramble shRNA. Results
M, n = 3. For statistical analyses, an unpaired Student’s t test was used. *p <
a scramble shRNA. Results are expressed as pmol CO2/h/mg of protein. Data
test was used. **p < 0.01.
control Flvcr1afl/fl mice after tamoxifen injection. Specific primers allowed the
cr1a. Deletion of the first exon of Flvcr1a gene mediated by CRE recombinase
g of mitochondrial proteins. Tumor endothelial cells (TECs) isolated by sub-
vcr1afl/fl;Cdh5(PAC)-CreERT2 indicated as Flvcr1a-KO) are compared with TECs
± SEM, n = 2 pools of animals. For statistical analyses, an unpaired Student’s t
s isolated by subcutaneous tumors in tamoxifen-inducible endothelial specific
pared with TECs isolated by subcutaneous tumors in control Flvcr1afl/fl mice.
plex I, nmol reduced cytochrome c/min/mg of mitochondrial protein for com-
complex IV. Data represent means ± SEM, n = 2 pools of animals. For statistical
isolated by subcutaneous tumors in tamoxifen-inducible endothelial-specific
pared with TECs isolated by subcutaneous tumors in control Flvcr1afl/fl mice.
s ±SEM, n = 2 pools of animals. For statistical analyses, an unpaired Student’s
Article
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OPEN ACCESSpathological processes, encompassing cancer, obesity, neuro-
degenerative disorders, infections, muscular diseases, and dia-
betes among others. Several components or indirect modulators
of the TCA cycle may be exploited for therapeutic purposes and,
although high toxicity remains an issue, some of those ap-
proaches have proven to be well tolerated clinically (Anderson
et al., 2018). Our data identified the heme synthesis-export
axis as a potentially targetable vulnerability to modulate the
TCA-cycle flux. The fact that FLVCR1a is a plasma membrane
protein makes it a good candidate for the development of spe-
cific inhibitors/activators, particularly in the context of cancer,
in which this heme exporter is overexpressed compared with
that of normal tissues. Moreover, some U.S. Food and Drug
Administration (FDA)-approved drugs expected to inhibit/
enhance heme synthesis and heme export are already available
(Wachowska et al., 2011; Webber et al., 1999; Stein et al., 2017)
and could be used to interfere with cell metabolic adaptation in
various disease types. In conclusion, our work identifies the
heme synthesis-export axis as a key regulator of the TCA cycle
and oxidative metabolism and puts forth the potential targeting
of this system in various pathological settings.STAR+METHODS
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CD45 MicroBeads, mouse Miltenyi Biotec, Bergisch Gladbach, DE Cat#130-052-301
CD31 MicroBeads, mouse Miltenyi Biotec, Bergisch Gladbach, DE Cat#130-097-418
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Deposited data




BioXpress Wan et al., 2015 (https://hive.biochemistry.
gwu.edu/bioxpress)
N/A
Experimental models: Cell lines
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
Caco2 cells (ATCC, Manassas, VA USA, catalog n HTB-37, RRID:CVCL_0025) were maintained in Dulbecco’s modified Eagle’s me-
dium (DMEM, high glucose, GlutaMAX supplement; GIBCOby Thermofisher Scientific,Waltham,MAUSA, catalog n61965059) sup-
plemented with 20%heat-inactivated low-endotoxin fetal bovine serum (FBS; GIBCO by Thermofisher Scientific, Waltham,MAUSA,
catalog n10270106), 1 mM Sodium Pyruvate (GIBCO by Thermofisher Scientific, Waltham, MA USA, catalog n11360039) and 1X
MEM Non-essential amino acids solution (GIBCO by Thermofisher Scientific, Waltham, MA USA, catalog n11140035). SKCO1
(ATCC, Manassas, VA USA, catalog n HTB-39, RRID:CVCL_0626) were propagated in Minimal essential medium (MEM, GIBCO
by Thermo Fisher Scientific, Waltham, MA USA, catalog n21090022) supplemented with 10% heat-inactivated low-endotoxin
FBS (GIBCO by Thermofisher Scientific, Waltham, MA USA, catalog n10270106) and 2mM L-glutamine (Thermo Fisher Scientific,
Waltham,MAUSA, catalog n25030024). C80 cells (ECACC, Salisbury, UK catalog n 12022904, RRID:CVCL_5249) weremaintained
in Iscove’s modified Dulbecco’s medium (IMDM, GlutaMAX supplement; GIBCO by Thermo Fisher Scientific, Waltham, MA USA,
catalog n31980022), supplemented with 10% heat-inactivated low-endotoxin FBS (GIBCO by Thermofisher Scientific, Waltham,
MA USA, catalog n10270106). SHSY-5Y cells (ATCC, Manassas, VA USA, catalog n CRL-2266, RRID:CVCL_0019) were main-
tained in Dulbecco’s Modified Eagle Medium Nutrient Mixture F-12 (DMEM-F12, GIBCO by Thermo Fisher Scientific, Waltham,
MAUSA, catalog n31330038) supplementedwith 10%heat-inactivated low endotoxin FBS (GIBCOby Thermofisher Scientific, Wal-
tham, MA USA, catalog n10270106). BTECs (Grange et al., 2006) were maintained in EndoGRO-MV-VEGF Complete Culture Media
Kit (Merck Millipore, Burlington, MA USA, catalog n SCME003). LL/2 (LLC1) cells (ATCC, Manassas, VA USA, catalog n CRL-1642,
RRID:CVCL_4358) were cultured in Dulbecco’s modified Eagle’s medium (DMEM, high glucose, GlutaMAX supplement; GIBCO by
Thermofisher Scientific, Waltham, MA USA, catalog n 61965059) supplemented with 10% heat-inactivated low-endotoxin fetal
bovine serum (FBS; GIBCO by Thermofisher Scientific, Waltham, MA USA, catalog n10270106).
All cell media were ordinarily supplemented with antibiotics (100U/ml penicillin and 100mg/ml streptomycin; GIBCO by Thermo
Fisher Scientific, Waltham, MA USA, catalog n15140122). Cells were maintained in a 37C and 5% CO2 air incubator and routinely
screened for absence of mycoplasma contamination.
Animal models
Transgenic ApcMin/+ mice were from The Jackson Laboratory (Bar Harbor, ME USA; C57BL/6J-ApcMin/J, catalog n002020,
RRID:IMSR_JAX:002020).
For genotyping, primers Apc-Fw (50 CAAGTCTGCCATCCCTTCACGTTAGGAA 30) and Apc-Rev (50 TCGTTTATATTCCACTTTGG-
CATAAGGC 30) (Luo et al., 2009) were used to amplify the portion of Apc gene containing the ApcMin mutation (a transversion point
mutation that alters nucleotide 2549 in Apc mRNA: NM_001360980.1 from a T to an A, converting codon 850 from one encoding a
leucine to a stop codon). The obtained DNAwas then sequenced to discriminate mice for the presence of the mutated allele. Tumors
were collected in different tracts of the intestine of 17-week-old males.
NOD SCID gamma (NSG) mice were from The Jackson Laboratory (Bar Harbor, ME USA; NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, cat-
alog n005557, RRID: IMSR_JAX:005557). 8-week-old males were used for the experiments.
Tamoxifen-inducible endothelial specific Flvcr1a null mice (Flvcr1afl/fl;Cdh5(PAC)-CreERT2 mice, named Flvcr1a-KO in the text and
figures) were generated in our laboratory. Briefly, previously generated Flvcr1afl/fl mice (Vinchi et al., 2014) were crossed with
Cdh5(PAC)-CreERT2 mice (Tg(Cdh5-cre/ERT2)1Rha, MGI ID: 3848982, RRID:MGI:3848984) (Wang et al., 2010), kindly provided by
Ralf H. Adams, on a C57BL/6 background. Mice were genotyped by polymerase chain reaction (PCR) analyses on DNA from tail bi-
opsies. To detect the Cdh5-Cre allele, primers Cre-Fw (50 ACA CCT GCT ACC ATA TCA TCC TAC 30) and Cre-Rev (50 CAT CGA CCG
GTA ATG CAG 30) were used. To analyze the LoxP sites on Flvcr1 gene, primers ILox-Fw (5ʹ-TCTAAGGCCCAGTAGGACCC-3ʹ) and
ILox-Rev (5ʹ-GAAAGCATTTCCGTCCGCCC-3ʹ) were used, given a 280-bp band for the floxed allele and a 242-bp band for the wild-
type allele. To inactivate Flvcr1a selectively in endothelial cells, 6-week-old Flvcr1afl/fl;Cdh5(PAC)-CreERT2 males were treated
intraperitoneally with 1mg/day tamoxifen (Sigma Aldrich St. Louis, MO USA, catalog nT5648) for 3 consecutive days, followed by
3 additional days after a 4-days treatment free interval. To detect the Flvcr1a null allele resulting from Cdh5-Cre activity, primers
ILox-Fw (5ʹ-TCTAAGGCCCAGTAGGACCC-3ʹ) and IILox-Rev (5ʹ-AGAGGGCAACCTCGGTGTCC-3ʹ) were used, given a 320-bp frag-
ment. Tamoxifen-treated Flvcr1afl/fl mice were used as control.
All the mice were provided with food and water ad libitum. Experiments were performed on males.




Analyses on human samples databases
The frequency of tumors showing upregulated FLVCR1 expression with respect to their matched normal tissuewas determined using
the online tool BioXpress (Wan et al., 2015) (https://hive.biochemistry.gwu.edu/bioxpress). Only those samples that have matched
normal tissue expression datawere used for this analysis. Numbers of patients overexpressing FLVCR1 in tumor relative to total num-
ber of patients examined for that tumor subtype are indicated in the figure. A binomial test was performed to assess the statistical
significance of the number of patients overexpressing FLVCR1 in tumor relative to the total number of patients for that tumor subtype,
the null hypothesis being equal probability of FLVCR1 being up or downregulated in cancer for each patient.
In silico determination of FLVCR1 gene expression in colon adenocarcinoma and rectum adenocarcinoma human samples was
also performed by a direct analysis on data reported in The Cancer Genome Atlas (TCGA). In this case, for the evaluation of FLVCR1
expression in human tumors andmatched normal tissues, 41 and 8 primary colon and rectum tumors, respectively, were analyzed. A
paired Wilcoxon test was performed to assess the statistical significance of the difference in expression.
Gene silencing and overexpression
FLVCR1a silencing was performed as described in Destefanis et al. (2019). Briefly, different shRNAs for the human FLVCR1 tran-
scripts were tested. We selected the only one which specifically downregulates FLVCR1a, without targeting the FLVCR1b isoform
(TRC Lentiviral pLKO.1 Human FLVCR1 shRNA set RHS4533-EG28982, clone TRCN0000059599; Dharmacon, Lafayette, CO, USA).
To specifically downregulate ALAS1, two different shRNAs targeting the human ALAS1 transcript were used (TRC Lentiviral
pLKO.1 Human ALAS1 shRNA set RHS4533-EG211, clone TRCN0000045740, named shRNA ALAS1 in the figure, and
TRCN0000045738, named shRNA ALAS12 in the figure; Horizon Discovery, Cambridge, UK).
For control cells, a pLKO.1 lentiviral vector expressing a scramble shRNA (TRC Lentiviral pLKO.1 Non-targeting Control shRNA,
catalog n RHS6848; Dharmacon, Lafayette, CO, USA) was used.
Gene overexpression was performed as described in Bertino et al. (2019). Briefly, the FLVCR1a cDNA present in pCMV-SPORT6
vector (MGC human FLVCR1 sequence, clone 4417876, Horizon Discovery, Cambridge, UK, catalog n MHS6278-202757940) and
the Myc-tag sequence present in pcDNA3.1(-)/myc-His B (Thermofisher Scientific, Waltham, MA USA, catalog n V85520) were
cloned in frame in the pLVX-puro vector, a lentiviral expression vector with constitutively active human cytomegalovirus immediate
early promoter and the puromycin resistance gene (Clontech Laboratories Inc. A Takara Bio Company, Mountain View, CA, USA,
catalog number 632164), in order to obtain the pLVX-puro FLVCR1a vector. For control cells, a pLVX-puro empty vector (Clontech
Laboratories Inc. A Takara Bio Company, Mountain View, CA, USA, catalog number 632164) was used.
Following lentiviral transduction, cells were maintained in selective medium containing 0.002mg/ml puromycin (Puromycin dihy-
drochloride from Streptomyces alboniger, Sigma-Aldrich, St. Louis, MO USA, catalog n P8833).
Tumor-associated endothelial cells isolation
Tumor-associated endothelial cells (TECs) were isolated from Lewis lung carcinoma xenografted subcutaneous tumors in tamoxifen-
inducible endothelial specific Flvcr1a null mice (Flvcr1afl/fl;Cdh5(PAC)-CreERT2 mice, named Flvcr1a-KO in the text and figures) or
control (Flvcr1afl/fl) mice. Briefly, tumors were dissected and minced into 1–2mm fragments with a scalpel. Tissue pieces were incu-
bated at 37C for 60 minutes in 10mL of pre-warmed Dulbecco’s Phosphate Buffered Saline (DPBS) with Calcium and Magnesium
(Lonza Pharma & Biotech, Basel, CH, catalog n BE17-513F) and 2mg/ml Collagenase (Collagenase from Clostridium histolyticum,
Type I, Sigma Aldrich St. Louis, MOUSA, catalog nC0130), with regular shacking until a single cell suspension was obtained. During
this incubation, the cells were mechanically dissociated at 10minutes intervals by pipetting. To stop the collagenase activity, DMEM
(GIBCO by Thermofisher Scientific, Waltham, MA USA, catalog n 61965059) containing 10% FBS (GIBCO by Thermofisher Scien-
tific, Waltham, MA USA, catalog n10270106) was added to the cell suspension, gently pelleted, and rinsed with PBS. The cells in
PBS were then filtered through a 40mm Cell Strainer (Corning Life Sciences, Corning, NY USA, catalog n352340). Single-cell sus-
pension was centrifuged at 300 x g for 10 minutes and tumor-associated endothelial cells were isolated through MACS Technology
by using nano-sized MicroBeads, following the manufacturer instructions. Particularly, a negative selection was performed using
CD45 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, DE, catalog n130-052-301). CD45-negative cell fraction was then pelleted
and incubated with CD31 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, DE, catalog n130-097-418) to obtain endothelial cells.
Xenograft tumor model
For the SKCO1 xenograft model, 8-week-old NOD SCID gamma (NSG) mice (The Jackson Laboratory, Bar Harbor, ME USA;
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, catalog n 005557, RRID: IMSR_JAX:005557) were housed in a temperature-controlled, path-
ogen-free environment and used for experimentation. The mice were randomly divided into two groups (n = 6 per group). 5*106
SKCO1 cells, stably expressing a shRNA to FLVCR1a or to a scramble control sequence, were suspended in a solution 50%v/v
of PBS and matrigel (Corning Matrigel Basement Membrane Matrix, Corning Life Sciences, Corning, NY USA, catalog n 354234)
and then subcutaneously injected into the right flank of mice. After 11 weeks, mice were sacrificed and tumors were harvested. Tu-
mor length (L) and width (W) were measured and tumor volume (mm3) was calculated using the following formula: (L x W2)/2.e5 Cell Reports 35, 109252, June 15, 2021
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injected subcutaneously into the flanks of immunocompetent syngeneic (C57BL/6) tamoxifen-inducible endothelial specific Flvcr1a
null mice (Flvcr1afl/fl;Cdh5(PAC)-CreERT2mice, named Flvcr1a-KO in the text and figures) or control (Flvcr1afl/fl) mice. Both control and
inducible knockout mice were treated intraperitoneally with tamoxifen (Sigma Aldrich St. Louis, MO USA, catalog nT5648; 1mg/day
for 3 consecutive days and 3 additional days after a 4-days treatment free interval) one week before cancer cell injection.
All experimental procedures were approved by the Italian Ministry of Health.
Hematoxylin and eosin staining
Following harvesting, the tissue waswashedwith 0.1M phosphate-buffered saline (PBS). After overnight fixation in 4% formaldehyde
at 4C, the tissue was decalcified in 0.25M EDTA pH = 7.7 for several days and then embedded in paraffin. 5mm-thick paraffin sec-
tions were stained with hematoxylin and eosin (H&E) following standard procedures.
Cell viability assay
To assess cell viability, the CellTiter-Fluor Cell Viability Assay (Promega, Madison, WI USA, catalog nG6080) was used. The assay is
based on measurement of a conserved and constitutive protease activity within live cells and therefore serves as a biomarker of cell
viability unrelated to mitochondrial function. The detection of cell viability at different consecutive time points was regarded as a
readout of cell proliferation.
Crystal Violet staining
For crystal violet staining, 1*104 Caco2 cells were seeded in 6-well plates. Stainingwas performed at different time points for each cell
group in triplicate. Before staining, cells were washed in 0.1M PBS, fixed in 4%paraformaldehyde for 10 minutes. After PFA removal,
a 0.1% crystal violet (Sigma-Aldrich, St. Louis, MO USA) solution was applied for 10 minutes under room temperature. The plates
were rinsedwithwater until non color came off and then dried overnight at room temperature. Stained areawas assessed by analyses
of four representative photos per day for each triplicate using Fiji open source software (Schindelin et al., 2012) (https://fiji.sc/;
RRID:SCR_002285).
Apoptosis analysis
For cell apoptosis analyses, cells were synchronized in appropriate medium containing 0.1% FBS. The day after, serumwas re-intro-
duced. 48h hours after serum supplement, 5*105 cells were collected, washed in PBS, resuspended in 10mMHEPES, 140mMNaCl,
2.5mMCaCl2 buffer, and labeled with FITC Annexin 5 (Biolegend, San Diego, CAUSA, catalog n640906) for 20minutes. Then, 2ml of
propidium iodide (1mg/ml) (propidium iodide solution 1mg/ml in water, Sigma-Aldrich, St. Louis, MO USA, catalog n P4864) was
added.
Stained cells were analyzed using a FACSCanto II cytofluorimeter and processed with BD FACSDIVA Software v8.1 (BD Biosci-
ences, Milan, IT; https://www.bdbiosciences.com/instruments/software/facsdiva/index.jsp/; RRID:SCR_001456), acquiring at least
10,000 events per sample or 25,000 cells per sample for cell cycle experiments.
Hemin, 5-ALA and SA cell treatment
Hemin (Hemin Ferriprotoporphyrin IX chloride, Frontier Scientific, Logan, UT USA, catalog n H651-9) was freshly prepared by disso-
lution in cell culture-grade Dimethyl sulfoxide (DMSO, Sigma Aldrich, St. Louis, MO USA, catalog n276855) at a concentration of
4mM and then diluted in tissue culture medium at a concentration of 25mM.
5-ALA (5-Aminolevulinic acid hydrochloride, Sigma Aldrich, St. Louis, MO USA, catalog nA3785) was freshly prepared by disso-
lution in tissue culture medium at a concentration of 5mM.
SA (Succinyl-acetone, 4-6 Dioxoheptanoic acid, Sigma Aldrich St. Louis, MO USA, catalog nD1415) was freshly prepared by
dissolution in tissue culture medium at a concentration of 0.5mM.
All solutions were kept in the dark.
RNA extraction and quantitative real-time PCR analysis
RNA extraction and quantitative real-time PCR analyses were performed as described previously (Destefanis et al., 2019). Briefly,
total RNA was extracted using Purelink RNA mini kit (Thermofisher Scientific, Waltham, MA USA, catalog n 12183018A). Between
500 and 1000ng of total RNA were transcribed into complementary DNA (cDNA) by High-Capacity cDNA Reverse Transcription Kit
(Thermofisher Scientific, Waltham, MA USA, catalog n 4368813). Quantitative real-time PCR (qRT-PCR) was performed using the
Universal Probe Library system (Roche, Basel, CH). Primers and probes were designed using the ProbeFinder software (Roche,
Basel, CH, https://lifescience.roche.com/en_it/articles/Universal-ProbeLibrary-System-Assay-Design.html; RRID:SCR_014490).
For FLVCR1a and FLVCR1b, specific primers and the probe were designed using Primer Express Software v3.0 (Thermofisher Sci-
entific, Waltham, MA USA, https://www.thermofisher.com/order/catalog/product/4363991/; RRID:SCR_014326). qRT-PCR were
performed on a 7300 or 7900 Real Time PCRSystem (Thermofisher Scientific,Waltham,MAUSA). Transcript abundance, normalized
to 18 smRNA expression (for mouse tissues, mouse TECs and for BTECs) or to beta-actin mRNA expression (for cells, except TECs
and BTECs), is expressed as a fold increase over a calibrator sample.Cell Reports 35, 109252, June 15, 2021 e6
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To assess FLVCR1a and ALAS1 expression, cells were lysed by rotation for 30 minutes at 4C in RIPA buffer (150mM NaCl, 50mM
Tris-HCl pH 7.5, 1% Triton X-100, 0.5% Sodium deoxycholate, 0.1% SDS, 1mM EDTA). The buffer was freshly supplemented with
1mMphosphatase inhibitor cocktail (Sigma Aldrich, St. Louis, MOUSA, catalog n P0044), 1mMPMSF (Sigma Aldrich, St. Louis, MO
USA, catalog n 93482-50ML-F) and protease inhibitor cocktail (Roche, Basel, CH, catalog n 04693116001). The cell lysate was clar-
ified by centrifugation for 10minutes at 4C. Protein concentration in the supernatant was assessed by Bradford assay. For FLVCR1a
detection, to remove protein glycosylation, 10mg of protein extracts were incubated 10 minutes at 37C with 1mL of PNGase-F from
Elizabethkingia meningoseptica (Sigma Aldrich, St. Louis, MO USA, catalog n P-7367). Before loading on 4%–15%mini-PROTEAN
TGX precast gel (Bio-Rad, Hercules, CA USA, catalog n4568084), samples were incubated 5 minutes at 37C (for FLVCR1a detec-
tion) or 5 minutes at 95C (for ALAS1 detection) in 4X laemmli buffer freshly supplemented with 8% 2-mercaptoethanol. The primary
antibodies and dilutions are as follows: mousemonoclonal anti-FLVCR1 (C-4) (Santa Cruz Biotechnology, Dallas, TX USA, catalog n
sc-390100; 1:500), mouse monoclonal anti-ALAS-H (F5) (Santa Cruz Biotechnology, Dallas, TX USA, catalog n sc-137093; RRID:
AB_2225634; 1:1000) and mouse monoclonal anti-Vinculin (Sigma Aldrich, St. Louis, MO USA, catalog n SAB4200080; RRID:
AB_10604160, 1:8000). The revelation was assessed using the ChemiDoc Imaging System (Bio-Rad, Hercules, CA USA).
To assess luciferase expression, cells were lysed on ice for 30 minutes in a buffer containing 50mM Tris-HCl pH 7.4, 150mMNaCl,
1% Triton X-100, 0.2%SDS, protease, and phosphatase inhibitor cocktail. The cell lysate was clarified by centrifugation and 30 mg of
proteins were loaded on a Bis-Tris 4%–12% precast gel (Thermofisher Scientific, Waltham, MA USA). The primary antibodies and
dilutions are as follows: rabbit monoclonal anti-GAPDH (14C10) (Cell Signaling Technology, Danvers, MA USA, catalog n 2118;
RRID:561053; 1:5000) and mouse monoclonal anti-Firefly Luciferase (CS-17) (Thermofisher Scientific, Waltham, MA USA, 35-
6700; RRID:2533218; 1:500). The revelation was assessed using ImageQuant LAS 4000 (GE Healthcare, Chicago, IL, USA).
Zinc-mesoporphyrin washout experiments
Zinc-Mesoporphyrin (ZnMP) export studieswere performed, as described previously (Yang et al., 2010), by preloading cells for 30mi-
nutes at 37C with 5mM ZnMP (Zn(II) Mesoporphyrin IX, Frontier Scientific, Logan, UT USA, catalog nM40628) dissolved in cell cul-
ture-grade Dimethyl sulfoxide (DMSO, Sigma Aldrich St. Louis, MO USA, catalog n276855) at a concentration of 4mM and then
diluted to 5mM in working buffer (25mM HEPES (pH 7.4), 130mM NaCl, 10mM KCl, 1mM CaCl2, and 1mM MgSO4) freshly supple-
mented with 2.5mMAlbumin from human serum (HSA, Sigma Aldrich, St. Louis, MO USA, catalog nA3782). Cells were then washed
once with ice-cold working buffer containing 5% bovine serum albumin (BSA), and twice with ice cold working buffer, in order to re-
move the excess ZnMP not internalized by cells. Acquired intracellular fluorescence was determined on a Glomax Multi Detection
System (Promega Corporation, Madison WI, USA) with excitation at 405nm and emission at 580-640nm, upon lysis in TBS 1X-Triton
X-100 1%. Concomitantly, matched cell samples were washed three times and incubated in working buffer with 5mMHSA for 60 mi-
nutes at 37C to promote ZnMP export (washout phase).
After cells lysis in TBS 1X-Triton X-100 1%, samples residual intracellular fluorescence was determined on a Glomax Multi Detec-
tion System (PromegaCorporation,MadisonWI, USA) with excitation at 405nmand emission at 580-640nm. Datawere normalized to
total protein concentration in each sample. All experimental steps were performed in the dark. ZnMP retention was expressed as the
percentage residual intracellular fluorescence, measured upon washout, with respect to the starting fluorescence, detected imme-
diately after the uptake phase, in ZnMP loaded matched samples.
Measurement of heme concentration
Intracellular heme concentration wasmeasured using a fluorescence assay, as previously reported (Sinclair et al., 2001). Briefly, cells
untreated or treated for different timeswith 5-ALA or SAwere collected and 2Moxalic acid was added to them. Samples were heated
at 95C for 30minutes leading to iron removal from heme. Fluorescence (wavelength: excitation 405nm - emission 660-720nm) of the
resultant protoporphyrin was assessed on a Glomax Multi Detection System (Promega Corporation, Madison WI, USA).
The endogenous protoporphyrin content (measured in parallel unheated samples in oxalic acid) was subtracted. Data were
normalized to total protein concentration in each sample. Results were expressed as relative fluorescence intensity or, alternatively,
as pmol of heme/mg total protein.
Metabolome analysis
Metabolome analysis (C-SCOPE/CARCINOSCOPE - Absolute Quantitative Analysis of Energy Metabolism) was performed by The
Human Metabolome Technology (Yamagata, JP).
Assessment of metabolites levels
The levels of metabolites, except oxaloacetate, were determined by metabolome analyses (C-SCOPE/CARCINOSCOPE - Absolute
Quantitative Analysis of Energy Metabolism, The Human Metabolome Technology, Yamagata, JP) and expressed as mmol/g cellular
proteins. The levels of oxaloacetate were measured by the Oxaloacetate Assay Kit (Abcam, Cambridge, UK, catalog n ab83428), as
per manufacturer’s instructions, and expressed as mmol/mg cellular proteins.e7 Cell Reports 35, 109252, June 15, 2021
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The levels of NAD+ and NADH were determined by metabolomic analyses (C-SCOPE/CARCINOSCOPE - Absolute Quantitative
Analysis of Energy Metabolism, The Human Metabolome Technology, Yamagata, JP) and expressed as mmoles/g cellular proteins.
13C-isotope labeling experiments
FLVCR1a-silenced and scramble shRNA-expressing cells were plated in six-well plates in 25mM glucose, 4mM glutamine and 1mM
pyruvate-containing DMEM (DMEM, high glucose, pyruvate; GIBCOby Thermofisher Scientific,Waltham,MAUSA, catalog n11995-
065) supplementedwith 10%FBSat 3x105 cells perwell. After 24 hours themediumwas replacedwith 10%FBS- and 1mMpyruvate-
supplemented DMEM containing 4mM unlabelled glutamine (DMEM, no glucose; GIBCO by Thermofisher Scientific, Waltham, MA
USA, catalog n11966-025) and 25mM 13C6-glucose (D-Glucose-
13C6, Santa Cruz Biotechnology, Dallas, TX USA, catalog n
 sc-
239643B) for 13C6-glucose-tracing experiments; alternatively, the medium was replaced with 10% FBS-supplemented DMEM con-
taining 25mM unlabelled glucose (DMEM, high glucose, pyruvate, no glutamine, GIBCO by Thermofisher Scientific, Waltham, MA
USA, catalog n21969-035) and 4mM 13C5-glutamine (L-Glutamine-
13C5, Sigma Aldrich, St. Louis, MO USA, catalog n
605166), for
13C5-glutamine tracing experiments. The labeled medium was maintained for time indicated in each figure caption. At the end of
the incubations, monolayers were rapidly washed three times with ice-cold PBS and extracted with 600ml of ice-cold extraction so-
lution, composed ofmethanol, acetonitrile andMilli-Qwater (5:3:2), for endo-metabolite determination. Cell extractswere centrifuged
at 16,000 x g for 20 minutes at 4C and the supernatants were analyzed by liquid chromatography-mass spectrometry (LC-MS). An
ExactiveOrbitrapmass spectrometer (Thermofisher Scientific,Waltham,MAUSA)was used together with a ThermoScientific Accela
HPLC system. The HPLC setup consisted of a ZIC-pHILIC column (SeQuant, 150mm3 2.1mm, 5mm, Merck KGaA, Darmstadt, DE)
with a ZIC-pHILIC guard column (SeQuant, 20mm3 2.1mm, Merck KGaA, Darmstadt, DE) and an initial mobile phase of 20% 20mM
ammonium carbonate, pH 9.4 and 80% acetonitrile. Cell extracts (5ml) were injected and metabolites were separated over a 15-mi-
nutes mobile phase gradient, decreasing the acetonitrile content to 20%, at a flow rate of 200 mL min1 and a column temperature
of 45C. The total analysis timewas 23minutes. Allmetaboliteswere detected across amass rangeof 75-1,000m/z using theExactive
mass spectrometer at a resolution of 25,000 (at 200 m/z), with electrospray ionization and polarity switching. Lock masses were
used and themass accuracy obtained for all metaboliteswas below 5p.p.m.Datawere acquiredwith ThermoXcalibur software (Ther-
mofisher Scientific, Waltham, MA USA, https://www.thermofisher.com/order/catalog/product/OPTON-30965#/OPTON-30965).
The peak areas of different metabolites were determined with Thermo LCQUAN software (Thermofisher Scientific, Waltham,
MA USA, https://www.thermofisher.com/order/catalog/product/LCQUAN25?SID=srch-srp-LCQUAN25#/LCQUAN25?SID=srch-srp-
LCQUAN25), identified by the exactmass of each singly charged ion and by the known retention time on theHPLCcolumn, obtained by
running commercial standards of all metabolites detected. The 13C labeling patterns were determined bymeasuring peak areas for the
accurate mass of each isotopologue of several metabolites. Peak areas of each metabolite were normalized to the protein content in
each well measured, at the end of the experiment, using the Lowry assay.
Mitochondria isolation
According to Wibom et al. (2002), cells were washed twice in ice-cold 0.1M phosphate-buffered saline (PBS), then lysed in 0.5mL
buffer A (50mmol/L Tris, 100mmol/L KCl, 5mmol/L MgCl2, 1.8mmol/L ATP, 1mmol/L EDTA, pH 7.2), supplemented with protease
inhibitor cocktail III [100 mmol/L AEBSF, 80mmol/L aprotinin, 5mmol/L bestatin, 1.5mmol/L E-64, 2mmol/L leupeptin and 1mmol/
L pepstatin (Merck KGaA, Darmstadt, DE)], 1mmol/L phenylmethylsulfonyl fluoride (PMSF), 250mmol/L NaF. Samples were clarified
by centrifuging at 650 x g for 3 minutes at 4C, and the supernatant was collected and centrifuged at 13,000 x g for 5 minutes at 4C.
The new supernatant was discarded, the pellet containing mitochondria was washed in 0.5mL buffer A and re-suspended in 0.25mL
buffer B (250mmol/L sucrose, 15 mmol/L K2HPO4, 2mmol/L MgCl2, 0.5mmol/L EDTA, 5% w/v bovine serum albumin). A 100 mL
aliquot was sonicated and used for the measurement of protein content and the enzymatic activities of citrate synthase, a-ketoglu-
tarate dehydrogenase, succinate dehydrogenase and malate dehydrogenase. The remaining not-sonicated part was used to mea-
sure the electron transport chain (ETC) complexes I-IV activities.
Citrate synthase, a-ketoglutarate dehydrogenase, succinate dehydrogenase and malate dehydrogenase activities
The enzymatic activities of citrate synthase, a-ketoglutarate dehydrogenase, succinate dehydrogenase and malate dehydrogenase
were measured on 10mg mitochondrial proteins using the Citrate Synthase Assay Kit (Sigma Aldrich, St. Louis, MO USA, catalog n
MAK193), Alpha Ketoglutarate (alpha KG) Assay Kit (Abcam, Cambridge, UK, catalog n ab83431), Malate Dehydrogenase Assay Kit
(Sigma Aldrich, St. Louis, MO USA, catalog n MAK196), Succinate Dehydrogenase Activity Colorimetric Assay Kit (BioVision, Mil-
pitas, CA USA, catalog n K660), as per manufacturer’s instructions. Results were expressed as mU/mg mitochondrial proteins.
Activity of mitochondrial ETC complexes I-IV
The activity of mitochondria respiration complexes was measured according to Wibom et al. (2002).
Oxygen consumption rate measurement
Oxygen consumption rate (OCR) wasmeasured with a XFe96 Extracellular Flux Analyzer (Seahorse Bioscience, Billerica, MA, USA)
in 104 cells/well. The growthmediumwas replacedwith 180 mL of bicarbonate-freeDMEMsupplementedwith 10mMglucose, 2mMCell Reports 35, 109252, June 15, 2021 e8
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nide-4 (triluoromethoxy) phenylhydrazone (FCCP, 0.8 mM), and rotenone (1 mM) + antimycin A (1 mM) were injected into each well
sequentially to assess respectively coupling of respiratory chain, maximal and non-mitochondrial oxygen consumption. OCR
values were normalized to protein content in each well, determined with BCA assay.
Measurement of total cellular ATP levels
Total cellular ATP levels were determined bymetabolomic analyses (C-SCOPE/CARCINOSCOPE - Absolute Quantitative Analysis of
Energy Metabolism, The Human Metabolome Technology, Yamagata, JP) and expressed as mmoles/g cellular proteins.
Measurements of cytosolic ATP levels
The cytosolic ATP level was determined using a luciferase-based method as previously described (Morciano et al., 2017). Cells were
transfected with cytosolic-targeted luciferase encoding plasmid. After 36 hours, cells were perfused with KRB buffer, supplemented
with 1mMCaCl2 and 20mMD-luciferin (Beetle luciferin, potassium salt, Promega, Madison, WI USA, catalog n
E1605). The lumines-
cence values obtained upon addiction of luciferin correspond to the amount of ATP in the cytosolic compartment.
ATP levels in mitochondria and activity of mitochondrial ATP-synthase
Mitochondrial ATP levels were measured using a luciferase probe targeted to the mitochondrial matrix (mt-LUC) (Jouaville et al.,
1999; Morciano et al., 2017). Cells were perfused with KRB buffer, supplemented with 1mMCaCl2 and 20mMD-luciferin (Beetle lucif-
erin, potassium salt, Promega,Madison,WI USA, catalog nE1605) (plateau I). To evoke ATP production, cells were perfusedwith the
same luciferin solution plus 100 mM ATP (plateau II). Basal mitochondrial ATP content (plateau I) and mitochondrial ATP levels after
Ca2+-dependent stimulation (plateau II) were expressed as luminescence values.
The activity of mitochondrial ATP-synthase was indirectly assessed measuring the accumulation of mitochondrial ATP over the
basal ATP levels, upon stimulation of ATP synthesis (plateau II - plateau I).
Alternatively, ATP levels in mitochondria extracts were assessed by the ATP Bioluminescent Assay Kit (Sigma-Aldrich, St. Louis,
MO USA, catalog n FLAA). In this case, ATP was quantified as relative light units (RLU) and converted into nmol ATP/mg mitochon-
drial proteins, according to the calibration curve previously set.
Adenine nucleotide translocases (ANTs) activity
The activity of ANTs was measured fluorimetrically on 250mg mitochondrial proteins according to Kawamata et al. (2010). Results
were expressed as mmoles exchanged ATP/mg mitochondrial proteins.
Tricarboxylic acid (TCA) cycle flux
The glucose flux through TCA cycle was measured by radiolabeling cells with 2 mCi/ml [6-14C]-glucose (55mCi/mmol; PerkinElmer,
Waltham, MA, USA, catalog n NEC045X). Cell suspensions were incubated for 1 hour in a closed experimental system to trap the
14CO2 developed from [
14C]-glucose. The reaction was stopped by injecting 0.5ml of 0.8N HClO4. The amount of glucose trans-
formed into CO2 through the TCA cycle was calculated as described (Riganti et al., 2004) and expressed as pmoles CO2/h/mg
cell proteins.
Glutaminase (GLS) and glutamine synthetase (GLUL) activity
Glutamine catabolism was measured as reported (Curthoys and Weiss, 1974), with minor modifications, as detailed in Capello et al.
(2016). Briefly, cells were washed with PBS, detached by gentle scraping, centrifuged at 13,000 x g for 5 minutes at 4C, re-sus-
pended in 250mL of buffer A (150mmol/L KH2PO4, 63mmol/L Tris/HCl, 0.25mmol/L EDTA; pH 8.6) and sonicated. A volume of
100mL of the whole cell lysates was incubated for 30 minutes at 37C in a quartz cuvette, in the presence of 50mL of 20mmol/L L-
glutamine and 850mL of buffer B (80mmol/L Tris/HCl, 20mmol/L NAD+, 20mmol/L ADP, 3% v/v H2O2; pH 9.4). The absorbance of
NADH was monitored at 340nm using a Lambda 3 spectrophotometer (PerkinElmer, Waltham, MA USA). The kinetics was linear
throughout the assay. The results were expressed as mmol NADH/min/mg cell proteins, and were considered as an index of the ac-
tivity of glutaminase (GLS) plus L-glutamic dehydrogenase (GLUDH). In a second series of samples, 20mL of the 30mmol/L GLS in-
hibitor bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl) ethyl sulfide (BPTES, Sigma Aldrich St. Louis, MOUSA, catalog n SML0601)
was added after 15minutes. This concentration was chosen as it produced 100% inhibition of GLS activity in our system (not shown).
The absorbance of NADHwasmonitored for 15minutes as described previously. The results, considered as an index of the activity of
GLUDH, were expressed as mmol NADH/min/mg cell proteins. GLS activity was obtained by subtracting the rate of the second assay
from the rate of the first one.
The enzymatic activity of glutamine synthetase (GLUL) wasmeasured spectrophotometrically, using theGlutamine SynthetaseMi-
croplate Assay Kit (Cohesion Biosciences Ltd, London, UK, catalog n CAK102). Results were expressed asmU/mg cellular proteins.
Fatty acids b-oxidation measurement
The rate of palmitic acid oxidation, considered an index of fatty acid b-oxidation, was measured by metabolic radiolabeling in
whole cell lysates as reported in Gaster et al. (2004). Briefly, cells were washed twice with PBS, detached with trypsin/EDTAe9 Cell Reports 35, 109252, June 15, 2021
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OPEN ACCESS(0.05/0.02% v/v) and centrifuged at 13,000 x g for 5 minutes. A 50mL aliquot was collected, sonicated and used for intracellular
protein quantification. The remaining sample was re-suspended in culture medium containing 0.24mmol/L fatty acid-free bovine
serum albumin, 0.5mmol/L L-carnitine, 20mmol/L HEPES, 2mCi [1-14C] palmitic acid (3.3mCi/mmol, PerkinElmer, Waltham, MA
USA, catalog n NEC075H) and transferred into test tubes that were tightly sealed with rubber caps. In each experimental set cells
were pre-incubated for 30 minutes with the carnitine palmitoyltransferase inhibitor etomoxir (1mmol/L, Sigma Aldrich St. Louis, MO
USA, catalog n E1905) or with the AMP-kinase activator 5-aminoimidazole-4-carboxamide ribonucleotide AICAR (1mmol/L,
Sigma Aldrich St. Louis, MO USA, catalog n A9978), as negative and positive controls, respectively. After 2 hours incubation
at 37C, 0.3mL of a 1:1 v/v phenylethylamine/methanol solution was added to each sample using a syringe, followed by
0.3mL 0.8N HClO4. Samples were incubated for a further 1 hour at room temperature, then centrifuged at 13,000 x g for 10 mi-
nutes. Both the supernatants, containing 14CO2, and the precipitates, containing
14C-acid soluble metabolites (ASM), were
collected. The radioactivity of each sample was counted by liquid scintillation. Results were expressed as pmol of [14CO2],
used as internal control, or 14C-ASM/h/mg cell proteins. In each experimental set, the amount of [14CO2] was always < 10%
than the amount of 14C-ASM.
Ketone bodies measurement
The amount of b-hydroxybutyrate, taken as an index of ketone bodies amount, was assessed in the whole cell lysate using the b-hy-
droxybutyrate Colorimetric Assay Kit (CaymanChemical, Ann Arbor,MI USA, catalog n 700190). Results were expressed as mmoles/
mg cellular proteins.
The amount of b-hydroxy-b-methylglutaryl-CoA was determined by metabolomic analyses (C-SCOPE/CARCINOSCOPE - Abso-
lute Quantitative Analysis of Energy Metabolism, The Human Metabolome Technology, Yamagata, JP) and expressed as mmoles/g
cellular proteins.
Mitochondrial biogenesis
Mitochondrial biogenesis was detected with the MitoBiogenesis In-Cell ELISA Kit_Colorimetric (Abcam, Cambridge, UK, catalog n
ab110217).
Additionally, parameters describing the mitochondrial network dynamics were measured, including number of mitochondrial ob-
jects, total mitochondrial volume and mean volume of single mitochondrial object. Control and FLVCR1a-silenced Caco-2 cells were
seeded and transfected with mitochondria-targeted Discosoma sp. red fluorescent protein (mtDsRed) (Gotoh et al., 2004) to specif-
ically mark the mitochondrial compartment. Protein expression was allowed for 36 hours and then cells were imaged with the same
microscope used for measurements of membrane potential. 21 planes with 0.6 mm distance z stacks were acquired to allow acqui-
sition of the whole cell. After acquisition, images were restored with the Autoquant 3D-blind deconvolution module, installed on NIS-
Elements (Nikon Instruments Inc.), using a theoretical PSF. After restoration, images were loaded in Imaris v4.0 (Bitplane AG, Zurich,
CH, http://www.bitplane.com/imaris/imaris/; RRID:SCR_007370) then subtracted of background, and used to generate a threshold-
based isosurface object group.
Mitochondrial basal calcium levels measurement
Themitochondrial basal calcium levels were determined as described in Marchi et al. (2019). Briefly, cells were grown on 24mm cov-
erslips and transfected with mitochondrial-targeted GCaMP6m (mt- GCaMP6m) encoding plasmid (Patron et al., 2014; Marchi et al.,
2019). Imaging was performed on Cell̂ Sense multiple wavelength high-resolution fluorescence microscopy system, using a 40x
objective. Cells were alternatively illuminated at 474 and 410nmand fluorescencewas collected through a 515/30nmband pass filter.
Analysis was performed with the Fiji open source software (Schindelin et al., 2012) (https://fiji.sc/; RRID:SCR_002285). Data are pre-
sented as the mean of the averaged ratio of all time points.
Mitochondrial calcium uptake measurement
The mitochondrial calcium uptake was determined as previously described (Bonora et al., 2013). Briefly, cells were seeded onto
13mm glass coverslips and transfected with a mitochondrial-targeted Aequorin probe (mt-AEQ) (Rizzuto et al., 1992; Bonora
et al., 2013). Before the measurement, cells were incubated with 5 mM coelenterazine for 1.5 hour in KRB buffer supplemented
with 1mM CaCl2, and then transferred to the perfusion chamber. Cells were stimulated using IP3-dependent agent (ATP 100 mM)
in order to evoke Ca2+ discharge from the Endoplasmic Reticulum and rapid Ca2+ accumulation inside mitochondria. The experi-
ments were terminated by lysing cells with Triton X-100 in a hypotonic Ca2+-rich solution, thus discharging the remaining aequorin
pool. The light signal was collected and calibrated into [Ca2+] values by an algorithm based on the Ca2+ response curve of aequorin at
physiological conditions of pH, [Mg2+], and ionic strength.
Mitochondrial membrane potential measurements
Mitochondrial membrane potential was measured by the Tetramethylrhodamine, methyl ester (TMRM) fluorescent dye-based
method. Cells were loaded with 20nM Tetramethylrhodamine methyl ester perchlorate (TMRM, Sigma Aldrich St. Louis, MO USA,
catalog n T5428) for 30 minutes at 37C. Successively, cells were imaged with Nikon Swept Field Confocal equipped with CFI
Plan Apo VC60XH objective (n.a. 1.4) and an Andor DU885 EM-CCD camera, controlled by the NIS-Elements 3.2. Basal levelsCell Reports 35, 109252, June 15, 2021 e10
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St. Louis, MO USA, catalog n C2920).
Additionally, the data were confirmed measuring mitochondrial membrane potential by the JC-1 fluorescent dye-based method
(JC-1 Dye_Mitochondrial Membrane Potential Probe, Thermofisher Scientific, Waltham, MA USA, catalog n T3168) on a high
throughput system (Olympus Scan̂ R system). Cells were loaded with 25 mM JC-1 for 30 minutes at 37C, and then automatically
imaged using a 20x objective. The ratio of red to green fluorescence has been reported.
QUANTIFICATION AND STATISTICAL ANALYSIS
Sample size, mean and statistical details of experiments can be found in the figure legends.
Statistical analyses were conducted in GraphPad Prism v5.0 and v7.0 (GraphPad Software, Inc., La Jolla, CA USA, https://www.
graphpad.com/; RRID:SCR_002798), or reported by the computational tools. No statistical method was used to predetermine sam-
ple size in studies.e11 Cell Reports 35, 109252, June 15, 2021
